EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure

Jessica R Golbus, Kensey Gosch, Mary C Birmingham, Javed Butler, Ildiko Lingvay, David E Lanfear, Antonio Abbate, Mikhail L Kosiborod, C V Damaraju, James L Januzzi, John Spertus, Brahmajee K Nallamothu

JACC: Heart Failure · 2023-11 · 11 (11) · 1521-1530

DOI: 10.1016/j.jchf.2023.05.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2023-11. Verfasst von Jessica R Golbus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Michigan Integrated Center fo…. Hauptthemen laut MEDLINE: Heart Failure, Wearable Electronic Devices. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NHLBI NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Wearable devices are increasingly used in research and clinical care though the relevance of their data in the context of validated outcomes remains unknown. OBJECTIVES: The purpose of this study was to characterize the relationship between smartwatch activity and patient-centered outcomes in patients with heart failure. METHODS: CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure) was a randomized-controlled clinical trial that enrolled participants with heart failure and a compatible smartphone. Participants were provided a Fitbit Versa 2 and completed serial Kansas City Cardiomyopathy Questionnaires (KCCQs) through a smartphone application. We evaluated the relationship between daily step count and floors climbed and KCCQ total symptom (TS) and physical limitation (PL) scores at baseline and their respective changes between 2 and 12 weeks using linear regression models, with restricted cubic splines for nonlinear associations. RESULTS: In total, 425 patients were included: 44.5% women, 40.9% with reduced ejection fraction. Baseline daily step count increased across categories of KCCQ-TS scores (2,437.6 ± 1,419.5 steps/d for scores 0 to 24 vs 4,870.9 ± 3,171.3 steps/d for scores 75 to 100; P < 0.001) with similar results for KCCQ-PL scores. This relationship remained significant for KCCQ-TS and KCCQ-PL scores after multivariable adjustment. Importantly, changes in daily step count were significantly associated with nonlinear changes in KCCQ-TS (P = 0.004) and KCCQ-PL (P = 0.003) scores. Floors climbed was associated with baseline KCCQ scores alone. CONCLUSIONS: Daily step count was nonlinearly associated with health status at baseline and over time in patients with heart failure. These results may inform interpretation of wearable device data in clinical and research contexts. (A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure [CHIEF-HF]; NCT04252287).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureWearable Electronic DevicesHumansFemaleMaleQuality of LifeCanagliflozinHealth StatusPatient Reported Outcome MeasuresStroke Volume

Stichwörter der Autor:innen

heart failuremobile technologypatient-reported outcomesphysical activitywearable device

Substanzen

Canagliflozin

Autor:innen und Institutionen

  • Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP), University of Mic…
  • University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Baylor Scott and White Research Institute, Dallas, Texas, USA.
  • Department of Internal Medicine, Division of Endocrinology and Peter O'Donnel Jr School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Cardiovascular Medicine and Center for Individualized and Genomic Medicine Research, Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.

Förderung

  • NHLBI NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Golbus, J. R., Gosch, K., Birmingham, M. C., Butler, J., Lingvay, I., Lanfear, D. E., Abbate, A., Kosiborod, M. L., Damaraju, C. V., Januzzi, J. L., Spertus, J., & Nallamothu, B. K. (2023). Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure. JACC: Heart Failure, 11(11), 1521-1530. https://doi.org/10.1016/j.jchf.2023.05.033

Vancouver

Golbus JR, Gosch K, Birmingham MC, Butler J, Lingvay I, Lanfear DE, et al. Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure. JACC: Heart Failure. 2023;11(11):1521-1530. doi:10.1016/j.jchf.2023.05.033

BibTeX
@article{Golbus2023,
  author = {Golbus, Jessica R and Gosch, Kensey and Birmingham, Mary C and Butler, Javed and Lingvay, Ildiko and Lanfear, David E and Abbate, Antonio and Kosiborod, Mikhail L and Damaraju, C V and Januzzi, James L and Spertus, John and Nallamothu, Brahmajee K},
  title = {Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure},
  journal = {JACC: Heart Failure},
  year = {2023},
  volume = {11},
  number = {11},
  pages = {1521--1530},
  doi = {10.1016/j.jchf.2023.05.033}
}
Kostenlos starten →